A. Castillo

发表

The retinoid X receptor ligand restores defective signalling by the vitamin D receptor

A. Aranda, Ruth Sánchez-Martínez, A. Steinmeyer, 2006, EMBO reports.

Differential regulation of pituitary-specific gene expression by insulin-like growth factor 1 in rat pituitary GH4C1 and GH3 cells.

A. Aranda, A. Castillo, 1997, Endocrinology.

The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors

J. Martínez-Orgado, J. Fernández-Ruiz, J. Romero, 2010, Neurobiology of Disease.

Differentiation of Lactotrope Precursor GHFT Cells in Response to Fibroblast Growth Factor-2*

M. Karin, A. Aranda, D. Palacios, 2000, The Journal of Biological Chemistry.

Characterization of vitamin D receptor ligands with cell-specific and dissociated activity.

A. Aranda, Ruth Sánchez-Martínez, A. Steinmeyer, 2006, Molecular endocrinology.

Dissociated Activity Characterization of Vitamin D Receptor Ligands with Cell-Specific and

Ruth Sánchez-Martínez, A. Steinmeyer, A. Castillo, 2006 .

Vitamin D-Dependent Recruitment of Corepressors to Vitamin D/Retinoid X Receptor Heterodimers

A. Zambrano, A. Aranda, Ruth Sánchez-Martínez, 2008, Molecular and Cellular Biology.

Cannabinoid CB2 receptors in human brain inflammation

J. Romero, A. Castillo, C. Benito, 2008, British journal of pharmacology.

Histone acetylation influences thyroid hormone and retinoic acid-mediated gene expression.

A. Aranda, A. Castillo, A. M. Jiménez-Lara, 1997, DNA and cell biology.

Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets

J. Martínez-Orgado, R. Pertwee, J. Romero, 2008, Pediatric Research.

Insulin-like growth factor-1 stimulates rat prolactin gene expression by a Ras, ETS and phosphatidylinositol 3- kinase dependent mechanism

A. Aranda, A. Castillo, R. Tolón, 1998, Oncogene.

β−Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR‐α, PPAR‐γ and TRPV1, but not CB1 or CB2 receptors

B. Cravatt, J. Martínez-Orgado, J. Romero, 2012, British journal of pharmacology.

Activation of the Prolactin Gene by Peroxisome Proliferator-activated Receptor-α Appears to Be DNA Binding-independent*

A. Aranda, A. Castillo, R. Tolón, 1998, The Journal of Biological Chemistry.

Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3.

S. Tenbaum, A. Aranda, J. Nevado, 2007, Journal of molecular endocrinology.

The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages

J. Martínez-Orgado, J. Romero, A. Castillo, 2009, Brain Research.

A Permissive Retinoid X Receptor/Thyroid Hormone Receptor Heterodimer Allows Stimulation of Prolactin Gene Transcription by Thyroid Hormone and 9-cis-Retinoic Acid

A. Aranda, J. Moreno, D. Palacios, 2004, Molecular and Cellular Biology.

Association with Ets-1 Causes Ligand- and AF2-Independent Activation of Nuclear Receptors

A. Aranda, Rosa M. Tolón, Ana I. Castillo, 2000, Molecular and Cellular Biology.

Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3.

S. Tenbaum, A. Aranda, J. Nevado, 2007, Journal of molecular endocrinology.

Synergistic activation of the prolactin promoter by vitamin D receptor and GHF-1: role of the coactivators, CREB-binding protein and steroid hormone receptor coactivator-1 (SRC-1).

A. Aranda, A. Castillo, R. Tolón, 1999, Molecular endocrinology.

Growth factor ligands of tyrosine kinase receptors activate the Rous sarcoma virus promoter by a Ras- and Raf-dependent mechanism.

A. Aranda, A. Castillo, J. Cosgaya, 1997, Gene.

Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3.

S. Tenbaum, A. Aranda, J. Nevado, 2007, Journal of molecular endocrinology.

β−Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR‐α, PPAR‐γ and TRPV1, but not CB1 or CB2 receptors

B. Cravatt, J. Martínez-Orgado, J. Romero, 2012, British journal of pharmacology.